发明申请
US20160120976A1 COMBINATION THERAPY WITH ANTI-CD74 AND ANTI-CD20 ANTIBODIES IN PATIENTS WITH RELAPSED AND REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA
审中-公开
与抗CD74和抗CD20抗体联合治疗患有相关和耐药性B细胞非霍奇金淋巴瘤的患者
- 专利标题： COMBINATION THERAPY WITH ANTI-CD74 AND ANTI-CD20 ANTIBODIES IN PATIENTS WITH RELAPSED AND REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA
- 专利标题（中）： 与抗CD74和抗CD20抗体联合治疗患有相关和耐药性B细胞非霍奇金淋巴瘤的患者
-
申请号： US14992528申请日： 2016-01-11
-
公开(公告)号： US20160120976A1公开(公告)日： 2016-05-05
- 发明人: David M. Goldenberg , William A. Wegener
- 申请人： Immunomedics, Inc.
- 主分类号： A61K39/395
- IPC分类号： A61K39/395 ; A61K31/425 ; A61K31/167 ; A61K31/135 ; A61K31/573 ; A61K31/133
摘要：
The present invention concerns methods of treating relapsed/resistant non-Hodgkin's lymphoma using combination therapy with an anti-CD20 antibody or fragment and an anti-CD74 antibody or fragment. In preferred embodiments, the antibody combination is administered along with at least one other therapeutic agent. The combination is effective to treat indolent NHL that is resistant to or relapsed from at least one therapy for NHL, including but not limited to rituximab resistant NHL. The antibody combination may be administered to human subjects at specific dosages and dosing schedules, that are effective to treat the disease but do not induce a dose-limiting toxicity.
信息查询
